

Please amend Claim 2, so that the text of the amended claim reads as follows.

2.(twice amended) An isolated nucleic acid molecule comprising a nucleotide sequence that:

- 31
- (a) encodes the amino acid sequence shown in SEQ ID NO:2; and
 - (b) hybridizes under highly stringent conditions with wash conditions of 0.1xSSC/0.1%SDS at 68°C to the nucleotide sequence molecule of SEQ ID NO: 1 or the complete complement thereof.
-

RESPONSE

I. Status of the Claims

Claims 4-5 have been cancelled as drawn to a non-elected invention. Claim 2 has been amended. Claims 2, 3, 6 and 7 are therefore presently pending in the case. For the convenience of the Examiner, a clean copy of the pending claims is attached hereto as **Exhibit A**. In compliance with 37 C.F.R. § 1.121(c)(1)(ii), a marked up copy of the original claims is attached hereto as **Exhibit B**.

II. Support for the Claims

Claim 2 has been amended to include the term molecule as requested by the Examiner. Support for this claim can be found throughout the specification as originally filed, with particular support being found at least in Claim 2 as originally filed and at page 4 lines 24-25.

As the amendment to Claim 2 is fully supported by the specification and claims as originally filed and as such do not constitute new matter. Entry therefore is respectfully requested.

III. Rejection of Claims Under 35 U.S.C. § 101

The Final Action continues to reject claims 2, 3, 6 and 7 under 35 U.S.C. § 101, as allegedly lacking a patentable utility due to not being supported by a specific, substantial, and credible utility or, in the alternative, a well-established utility. Applicants respectfully continue to traverse.

The Final Action disagrees with Applicants' logical assertion, based on the evidence, that the sequences of the present invention

have a number of substantial and credible utilities, in particular those which relate to polymorphisms identified in the sequences of the present invention that were described in the specification at page at page 16, line 21-31 and reiterated in Applicants' Previous Response.

The Final Action discounts Applicants' assertion regarding the use of the presently claimed polynucleotides on DNA chips, based on the position that such a use would allegedly be generic. Applicants disagree and believe that the described polymorphisms enhance the utility of the sequences of the present invention. These polymorphisms have particular, specific utility in DNA gene chip based analysis as they have been identified to contain several coding region single nucleotide polymorphisms (cSNPs), thus increasing their utility in DNA gene chip based analysis.

As set forth in Applicants First Response, given the widespread utility of such "gene chip" methods using *public domain* gene sequence information, there can be little doubt that the use of the presently described *novel* sequences would have great utility in such DNA chip applications. The claimed sequence provides a specific marker of the human genome (see evidence below), and that such specific markers are targets for discovering drugs that are associated with human disease. Thus, those skilled in the art would instantly recognize that the present nucleotide sequence would be an ideal, novel candidate for assessing gene expression using, for example, DNA chips, as the specification details.

Further evidence of utility of the presently claimed polynucleotide, although only one is needed to meet the requirements of 35 U.S.C. § 101 (*Raytheon v. Roper*, 220 USPQ 592 (Fed. Cir. 1983); *In re Gottlieb*, 140 USPQ 665 (CCPA 1964); *In re Malachowski*, 189 USPQ 432 (CCPA 1976); *Hoffman v. Klaus*, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988)), is the utility the present nucleotide sequence has a specific utility in determining the genomic structure of the corresponding human chromosome, for example mapping the protein encoding regions, as described in the specification and evidenced below. Clearly, the present polynucleotide provides exquisite specificity in localizing the specific region of the human chromosome containing the gene encoding the given polynucleotide, a utility not shared by virtually any other nucleic acid sequences (see evidence below). In fact, it is this specificity that makes this particular sequence so useful. Early gene mapping techniques relied on methods such as Giemsa staining to identify regions of chromosomes. However, such techniques produced genetic maps with a resolution of only 5 to 10 megabases, far too low to be of much help in identifying specific genes involved in disease. The skilled artisan readily appreciates the

significant benefit afforded by markers that map a specific locus of the human genome, such as the present nucleic acid sequence.

Only a minor percentage of the genome actually encodes exons, which in-turn encode amino acid sequences. The presently claimed polynucleotide sequence provides biologically validated empirical data (*e.g.*, showing which sequences are transcribed, spliced, and polyadenylated) that *specifically* define that portion of the corresponding genomic locus that actually encodes exon sequence. Equally significant is that the claimed polynucleotide sequence defines how the encoded exons are actually spliced together to produce an active transcript (*i.e.*, the described sequences are useful for functionally defining exon splice-junctions). The Applicants respectfully submit that the practical scientific value of expressed, spliced, and polyadenylated mRNA sequences is readily apparent to those skilled in the relevant biological and biochemical arts. For further evidence in support of the Applicants' position, the Examiner is requested to consider the evidence provided in Applicants' previous Response. The presently claimed polynucleotide sequence defines a biologically validated sequence that provides a unique and specific resource for mapping the genome as described in many articles.

As still further evidence supporting Applicants assertions of the specific utility of the sequences of the present invention in localizing the specific region of the human chromosome and identification of functionally active intron/exon splice junctions is the information provided in **Exhibit C**. This is the result of a blast analysis using SEQ ID NO:1 of the present invention when compared to the identified human genomic sequence. This result indicates that the sequence of the present invention is encoded by more than 7 exons spread non-contiguously along a region of human chromosome 20, at approximately 20q12, which are contained within partially overlapping clones, AL133463.16 and AL050320.19. Thus clearly one would not simply be able to identify the more than 7 protein encoding exons that make up the sequence of the present intention from within the large genomic sequence. Nor, would one be able to map the protein encoding regions identified specifically by the sequences of the present invention without knowing exactly what those specific sequences were.

Finally, the Examiner has determined that applicants argument of due process presented in previous response is not persuasive. Applicants understanding is that issued United States patents retain a legal presumption of validity which in this case indicates that the inventions claimed in the cited patents are *legally presumed* to be in full compliance with the provisions of 35 U.S.C. sections 101,

102, 103, and 112. Applicants respectfully submit that, absent a change in the law as enacted by Congress and signed by the President, it is improper for the Examiner to hold Applicants' invention to a different legal standard of patentability. Given the rapid pace of development in the biotechnology arts, it is difficult for the Applicants to understand how an invention fully disclosed and free of prior art at the time the present application was filed, could somehow retain *less* utility and be *less* enabled than inventions in the cited issued U.S. patents (which were filed during a time when the level of skill in the art was clearly lower). Simply put, Applicants invention is *more* enabled and retains *at least as much* utility as the inventions described in the claims of the U.S. patents of record. Any argument to the contrary is at best arbitrary and at worst capricious. Absent authority provided by an act of Congress or Executive order, arbitrary or capricious conduct by an administrative office the U.S. government has historically proven to conflict with the provisions of the U.S. Constitution. The Patent Office does not have the authority to rewrite U.S. law. However, the Patent Office does have a Constitutional obligation to administer U.S. law in an unbiased and procedurally consistent manner. That is what the Applicants are respectfully requesting the Examiner to consider in the present matter. As the issued U.S. Patents cited above are presumed to meet all of the requirements for patentability, including 35 U.S.C. §§ 101 and 112, first paragraph, Applicants respectfully submit that the presently claimed polynucleotide must also meet the requirements of 35 U.S.C. § 101.

For each of the foregoing reasons, Applicants submit that in light of the above discussion and those presented in previous Applicant responses, the presently claimed invention has been shown to have a substantial, specific, credible and well-established utility and that the rejection of pending claims 2, 3, 6 and 7 under 35 U.S.C. § 101 has been avoided, and respectfully request that the rejection be withdrawn.

IV Rejection of Claims Under 35 U.S.C. § 112, First Paragraph

The Action rejects claims 2, 3, 6 and 7 under 35 U.S.C. § 112, first paragraph, since allegedly one skilled in the art would not know how to use the invention, as the invention allegedly is not supported by a specific, substantial, and credible utility or a well-established utility. Applicants respectfully traverse. Applicants submit that as the claims have been shown to have a specific, substantial, credible and well established utility, as detailed in the section above, Applicants respectfully request that the rejection of claims 2, 3, 6 and 7 under 35 U.S.C. § 112, first paragraph, be withdrawn.

V Rejection of Claims Under 35 U.S.C. § 112, Second Paragraph

The Final Action rejects Claim 2 under 35 U.S.C. 112, second paragraph, on the basis that molecules, not sequences, hybridize.

Applicants submit that the use of the term "sequences" is sufficiently definite and would be known to those of skill in the art, however, solely in order to progress the case more rapidly toward allowance the claim has been revised to recite the term molecule, as the Examiner requests. Based on the foregoing, Applicants submit that Claim 2 is clearly sufficiently definite, and respectfully request withdrawal of this rejection.

VI. Conclusion

The present document is a full and complete response to the Final Action. In conclusion, Applicants submit that, in light of the foregoing amendments and remarks, the present case is in condition for allowance, and such favorable action is respectfully requested. Should Examiner Ramirez have any questions or comments, or believe that certain amendments of the claims might serve to improve their clarity, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

May 5, 2003

Date

James K. Ishimoto by David W. Hieber
DAVID W. HIEBER
REG. NO. 41,071

Lance K. Ishimoto
Attorney for Applicants

Reg. No. 41,866

LEXICON GENETICS INCORPORATED
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Exhibit B
Marked-Up Version of Amended Claims in
U.S. Patent Application Ser. No.09/863,824

1.(cancelled) An isolated nucleic acid molecule comprising at a nucleotide sequence encoding an amino acid sequence drawn from the group consisting of SEQ ID NOS: 2, 4 and 6.

2.(currently twice amended) An isolated nucleic acid molecule comprising a nucleotide sequence that:

(a) encodes the amino acid sequence shown in SEQ ID NO: 2; and

(b) hybridizes under highly stringent conditions with wash conditions of 0.1xSSC/0.1%SDS at 68°C to the nucleotide sequence molecule of SEQ ID NO: 1 or the complete complement thereof.

3. (original) An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:2.

4.(cancelled) An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:4.

5.(cancelled) An isolated nucleic acid molecule comprising a nucleotide sequence that encodes the amino acid sequence shown in SEQ ID NO:6.

6.(previously added) An expression vector comprising a nucleic acid sequence of Claim 3.

7.(previously added) A cell comprising the expression vector of Claim 6.